Scientists, from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, reported that the ever-changing “head” of the flu virus protein has an unexpected Achilles’ heel. TheRead More…
French pharmaceutical giant Sanofi recently announced that the key phase III clinical study ICARIA-MM to evaluate isatuximab in the treatment of recurrent/refractory multiple myeloma (R/R MM) has reached the main end point. TheRead More…
Kyowa Hakko Kirin, a Japanese pharmaceutical company, recently announced that the European Commission (EC) has approved Poteligeo (mogamulizumab) to treat adult patients with relapsed or refractory mycosis fugoides (MF) or Sezary syndromeRead More…
In the past decade, tumor immunotherapy has overturned the traditional concept of treatment, especially the discovery and application of immune checkpoint molecules. The immune checkpoint can be irritating or inhibitory, and theRead More…